ClinicalTrials.gg
RecruitingNCT07233239Updated Oct 29, 2026

A Study to Evaluate the Efficacy and Safety of Cannabidiol Oral Solution (CBD-OS [GWP42003-P, JZP926]) for the Treatment of Focal-Onset Seizures

A Phase 1 interventional study of CBD-OS in Focal Seizures, sponsored by Jazz Pharmaceuticals. Recruiting at 24 sites in United States. Open to participants aged 12 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-10-29.

Sponsored by Jazz Pharmaceuticals · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Nov 2025; still recruiting 11 months later.
Updated Oct 29, 2026Site recruiting status changed2 sites added+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
100
Allocation
Not applicable
Ages
12 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 13 studies testing cannabidiol in Seizures — 2 open to participants now, 2 under way, none of them phase 3. Cannabidiol · Seizures.

Planned enrollment
3rd of 13
100 · median 61
Started
2025
the only one that year
Phase 1
4 of 13
1 open now
Registered
13th of 13
by date
Lead sponsor
6 of 13
Jazz Pharmaceuticals

Among the 13 studies testing cannabidiol in Seizures, this one is the 3rd largest by planned enrollment, is the only one that started in 2025, is one of 4 in phase 1, and was the 13th registered.

Seizures

766 studies on the registry are indexed under Seizures; 134 are open to participants now.

Browse Seizures studies →

Open to participants now

2 of the 13 studies testing cannabidiol in Seizures are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About cannabidiol

Cannabidiol: first FDA approval 2018 (EPIDIOLEX), first EMA approval 2019. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 92 Seizures studies recruiting now, 35 (38%) set no upper age limit and 44 (48%) stop at 75 or younger; 38 take children under 18; 18 take healthy volunteers.

This study: 12 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies testing cannabidiol in Seizures, or all of them as a file.
02

Study summary

Cannabidiol oral solution (CBD-OS) is approved in the US for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS), or Tuberous sclerosis complex (TSC) in patients 1 year of age and older. This study will assess the efficacy and safety of CBD-OS in participants aged 12 to 75 years for the treatment of focal-onset seizures (FOS).

Read the detailed description

This study will assess the efficacy of CBD-OS as an adjunctive treatment in reducing the frequency of focal seizures compared to baseline as well as the effect of CBD-OS on health outcome endpoints in early line and refractory participants with FOS. This study will also examine pharmacokinetics (PK), safety, and potential predictors or mediators of treatment response, including functional magnetic resonance imaging (fMRI) and neuropsychological testing in a substudy.

03

Conditions studied

  • Focal Seizures

Browse trials for

Keywords

  • Focal Seizures
04

Who can participate

Ages eligible
12 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Participants are eligible to be included in the main study only if all of the following criteria apply:

  1. Participant has a documented diagnosis of focal epilepsy according to the ILAE Classification of Epilepsy, 2017, characterized by focal seizure types with typical interictal/ictal EEG findings (eg, history of an EEG with focal sharp waves or slowing). Participants with a documented diagnosis of focal epilepsy and a normal EEG are eligible for inclusion.
  2. Participant is currently treated with at least 1, but no more than 4, antiseizure medications on a stable regimen.
  3. Participant is aged 12 to 75 years old, inclusive, at Screening.

Participants are excluded from the study if any of the following criteria apply:

  1. Has a concurrent, confirmed diagnosis of non-epileptic seizures or events that can confound the assessment of the efficacy measures, in the opinion of the investigator.
  2. Has unstable medical condition(s), other than epilepsy.
  3. History of suicidal behavior, current suicidal risk as determined from history, or presence of active suicidal ideation as indicated by a positive response to Item 4 or Item 5 on the C-SSRS or is considered at risk of suicide or self-harm based on the clinical judgement of the investigator following interview with the participant and/or caregiver.
  4. Has known or suspected to cannabinoids or any of the of the study intervention, such as sesame oil.
  5. Is currently treated with Epidiolex or received treatment with Epidiolex within 28 days prior to Screening (Visit 1).
  6. Is currently using or has used recreational or medicinal cannabis, cannabinoid/CBD based medications, products, or supplements (botanical or synthetic) within 28 days prior to Screening (Visit 1) and/or is unwilling to abstain for the duration of the study.
  7. Presence of only nonmotor focal aware seizures or primary generalized epilepsies.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
100 participants (estimated)

Study arms

  • Experimental
    CBD-OS

    Participants who will receive open-label CBD-OS.

    Drug: CBD-OS

Interventions

  • DrugCBD-OS

    Starting dose of CBD-OS will be administered as per the approved local product label

    Also known as: GWP42003-P, JZP926

06

What researchers measure

Primary outcomes

  1. Percent change in countable focal seizure frequency compared to baseline

    Time frame: Baseline up to 16 weeks

07

Study locations

21 of 24 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

3 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2025 (actual). Primary completion is estimated for Nov 2027, 24 months after the start.

Of 16 phase 1 interventional studies under Seizures, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 56. This study's planned 24 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 14, 2025
First posted
Nov 18, 2025
StartActual
Nov 26, 2025
Primary completionEst.
Nov 29, 2027
CompletionEst.
Nov 29, 2027
Last update
Oct 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
2 sites added, 2 sites removed. 2 sites changed recruiting status (2 now recruiting)
Show 2 sites
  • Hackensack Meridian Neuroscience Institute at JFK University Medical Center · Edison, United StatesNot yet recruiting→Recruiting
  • Banner University Medical Center-Phoenix · Phoenix, United StatesNot yet recruiting→Recruiting
Show 2 added (2 United States)
  • Serenity Research Center, LLC · Miami, United States
  • Thomas Jefferson University · Philadelphia, United States
Show 2 removed
  • Onsite Clinical Solutions · Charlotte, United States
  • William S Middleton Memorial Veterans Hospital · Madison, United States
across 3 updates, Oct 2, 2026 – Oct 29, 2026
Show all 3 updates
  1. Oct 29, 2026
    2 sites added, 2 sites removed
    Show 2 added (2 United States)
    • Serenity Research Center, LLC · Miami, United States
    • Thomas Jefferson University · Philadelphia, United States
    Show 2 removed
    • Onsite Clinical Solutions · Charlotte, United States
    • William S Middleton Memorial Veterans Hospital · Madison, United States
  2. Oct 26, 2026
    Banner University Medical Center-Phoenix is now Recruiting
    + 1 other change: verification date
  3. Oct 2, 2026
    Hackensack Meridian Neuroscience Institute at JFK University Medical Center is now Recruiting
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07233239
Collaborators
Jazz Pharmaceuticals Research UK Ltd.
Responsible party
Sponsor
First posted
Nov 18, 2025
Start date
Nov 26, 2025
Primary completion
Nov 29, 2027 (estimated)
Completion
Nov 29, 2027 (estimated)
Last update
Oct 29, 2026

Study contacts

Clinical Trial Disclosure & Transparency
Contact
ClinicalTrialDisclosure@JazzPharma.com
215-832-3750

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cannabidiol

Start the discussion